TY - BOOK ID - 85633366 TI - Martindale : the complete drug reference PY - 2020 SN - 9780857113672 0857113674 PB - London, UK : Pharmaceutical Press, DB - UniCat KW - Farmaceutische wetenschappen KW - Pharmacologie KW - Farmacotherapie KW - Klinische farmacologie KW - 615 KW - Pharmaceutical Preparations KW - Pharmaceutic Preparations KW - Pharmaceutical Products KW - Pharmaceuticals KW - Preparations, Pharmaceutical KW - Drug KW - Drugs KW - Pharmaceutical KW - Pharmaceutical Preparation KW - Pharmaceutical Product KW - Preparation, Pharmaceutical KW - Preparations, Pharmaceutic KW - Product, Pharmaceutical KW - Products, Pharmaceutical KW - Pharmacology KW - Drug Dosage Calculations KW - Pharmacopoeias KW - Pharmacopées KW - Préparations pharmaceutiques KW - United Kingdom KW - Préparations pharmaceutiques. KW - Pharmacopoeias as Topic KW - Préparations pharmaceutiques. KW - Pharmaceutical Preparations. KW - United Kingdom. KW - Pharmacopoeia UR - https://www.unicat.be/uniCat?func=search&query=sysid:85633366 AB - The new edition of Martindale: The Complete Drug Reference, provides you with practical, evidence-based, global guidance, allowing you to quickly understand the characteristics of drugs and their clinical uses. Over 120 new monographs include : New antibacterials, such as delafloxacin, eravacycline, omadacycline, ozenoxacin, and plazomicin. Further antivirals, including drugs active against HIV (bictegravir, dapivirine, doravirine, ibalizumab), smallpox (tecovirimat), cytomegalovirus (letermovir), influenza (baloxavir marboxil), and hepatitis C (glecaprevir, pibrentasvir, voxilaprevir). New treatment options for migraine (erenumab, fremanezumab, galcanezumab), narcolepsy (solriamfetol), hyperkalaemia (sodium zirconium cyclosilicate), postpartum depression (brexanolone), eosinophilic asthma (benralizumab), hypoactive sexual desire disorder (bremelanotide), glaucoma (netarsudil), African trypanosomiasis (fexinidazole), and irritable bowel syndrome (tenapanor). New antidiabetic drugs, including ertugliflozin, evogliptin, semaglutide, and sotagliflozin .Further antineoplastics for treating cancers including PARP inhibitors (niraparib, rucaparib, talazoparib), PI3K inhibitors (alpelisib, copanlisib, duvelisib), and CAR-T therapies (axicabtagene ciloleucel, tisagenlecleucel). Novel targeted treatments for retinal dystrophy (voretigene neparvovec), neurotrophic keratitis (cenegermin), paroxysmal nocturnal haemoglobinuria (ravulizumab), hereditary transthyretin amyloidosis (inotersen, patisiran), spinal muscular atrophy (nusinersen), and hereditary angioedema (lanadelumab). ER -